// App-Quantinova.ai

569 : Outcomes of single versus double hormone receptor positive breast cancer.

Researchers

Presenter

  • Josee-Lyne Ethier

Principal Investigators

  • Maribel Casas

  • Maria Sanchez-Arago

  • Rosalia Caballero

  • Alvaro Rodriguez-Lescure

  • Amparo Ruiz

  • Emilio Alba

  • Lourdes Calvo

  • Manuel Ruiz

  • Ana Santaballa

  • Cesar Augusto Rodriguez

  • Carmen Crespo

  • Manuel Ramos Vazquez

  • Jose Manuel Gracia

  • Ana Lluch

  • Isabel Alvarez

  • Eva Maria Carrasco

  • Eitan Amir

  • Miguel Martin

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Albacete University Hospital, Albacete, Spain

  • GEICAM, Madrid, Spain

  • GEICAM Spanish Breast Cancer Group, Madrid, Spain

  • Hospital General de Elche, Alicante, Spain

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • IBIMA-Hospital Regional Universitario y Virgen de la Victoria, Malaga, Spain

  • Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Hospital Universitario La Fe de Valencia, Valencia, Spain

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Centro Oncologico de Galicia, A Coruna, Spain

  • Hospital de Cabuenes, Gijon, Spain

  • Hospital Clinico Universitario, Valencia, Valencia, Spain

  • Hospital Donostia, San Sebastian, Spain

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Hospital Universitario Quiron Madrid, Madrid, Spain

Locations

  • Canada

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved